AVI BioPharma (AVII) Announces AVI-4658 Phase 1b/2 Initial Efficacy Data
Tweet Send to a Friend
AVI BioPharma, Inc. (NASDAQ: AVII) today announced initial efficacy data from the ongoing Phase 1b/2 clinical trial of AVI-4658 for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
